Peter Schmid

Peter Schmid led the KEYNOTE-522 trial establishing pembrolizumab combined with neoadjuvant chemotherapy as a new standard of care for early-stage triple-negative breast cancer, demonstrating significant improvements in pathological complete response and event-free survival. His research has fundamentally altered the neoadjuvant treatment paradigm for TNBC, integrating immunotherapy with chemotherapy backbones. He continues to lead translational investigations into predictive biomarkers for immunotherapy benefit in TNBC. Schmid's work has driven global regulatory approvals for pembrolizumab in early TNBC.